Organoids Increase the Predictive Value of \textit{in vitro} Cancer Chemoprevention Studies for \textit{in vivo} Outcome

Rose N. Njoroge$^{1,2}$, Rajita J. Vatapalli$^{1,2}$ and Sarki A. Abdulkadir$^{1,2,3}$

$^1$Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, United States, $^2$Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States, $^3$Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States

Epidemiological and preclinical data suggest that antioxidants are protective against prostate cancer whose pathogenesis has been linked to oxidative stress. However, the selenium and vitamin E Cancer Prevention Trial (SELECT), found no efficacy for selenium in reducing prostate cancer incidence while vitamin E was associated with an increased risk of the disease. These results have called into question the models used in preclinical chemoprevention efficacy studies and their ability to predict \textit{in vivo} outcomes. Chemoprevention agents have traditionally been tested on two dimensional monolayer cultures of cell lines derived from advanced prostate cancers. But as SELECT demonstrates, results from advanced disease models were not predictive of the outcome of a primary chemoprevention trial. Additionally, lack of cell-matrix interactions in two dimensional cultures results in loss of biochemical and mechanical cues relevant for native tissue architecture. We use recent findings in three dimensional organoid cultures that recapitulated the SELECT trial results to argue that the organoid model could increase the predictive value of \textit{in vitro} studies for \textit{in vivo} outcomes.

\textbf{Keywords:} organoids, vitamin E, selenium, select, prostate cancer, anoikis, metabolism, extracellular matrix (ECM)

\section*{INTRODUCTION}

Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous male malignancy in the United States. One in six men in the US is expected to be diagnosed with PCa in his lifetime. In 2018, an estimated 164,690 men will be diagnosed with PCa and 29,430 men will die from the disease (1). For men with local or regional disease at diagnosis, radical prostatectomy, or radiation therapy are effective treatments with a 100\% 5-year survival rate (2). However, treatment related morbidity results in a poorer quality of life (3, 4). Moreover, 20–40\% radical prostatectomy and 30–50\% radiation therapy patients will experience biochemical recurrence within 10 years (5–7).

Early PCa growth and progression is driven by androgens making androgen deprivation therapy through surgical or medical castration, the standard treatment for advanced and metastatic PCa (8, 9). Eventually, however, there is progression to castration resistant disease, whose treatments confer a median overall survival benefit of less than 5 months (10–16). Moreover, widespread serum prostate-specific antigen screening has been associated with unnecessary biopsies, over diagnosis and overtreatment of indolent PCa (17). Given the drawbacks of screening, treatment associated morbidity and lack of effective treatments for advanced disease, preventing PCa is imperative.
The long natural history of PCa and its stepwise pathogenesis make it particularly amenable to prevention (2, 18, 19). Chemoprevention which uses natural, synthetic, or biological substances to reverse, slow or inhibit the initiation and progression of cancer, is an attractive public health strategy to reduce PCa incidence and treatment related morbidities (20). Androgen suppression using the 5α-reductase inhibitors, finasteride and dutasteride, in the Prostate Cancer Prevention Trial (PCPT) and REduction by DUtasteride of Prostate Cancer Events (REDUCE) randomized trials showed a 23 to 25% reduction in PCa relative risk (21, 22). These inhibitors were however not approved for PCa chemoprevention by the FDA as both were found to increase the risk of high-grade PCa with the possibility of increasing mortality (23). However, a long-term follow-up of the PCPT trial participants found a 43% relative risk reduction in low-grade PCa but no significant differences in overall survival or rates of high-grade disease (24). In spite of these findings, the two inhibitors are still not approved for PCa prevention (25).

**OXIDATIVE STRESS, A PROMISING CHEMOPREVENTION TARGET IN PCa**

Reactive oxygen species (ROS) are reactive molecules resulting from the partial reduction of molecular oxygen. Intracellular ROS comes from exogenous and endogenous sources (26). In small quantities, ROS take part in signal transduction by reversibly oxidizing protein thiol groups affecting numerous physiological processes (27, 28). High levels of ROS however indiscriminately damage cellular macromolecules (29). ROS can modify DNA bases, form DNA adducts, induce DNA cross-linking and cause DNA strand breaks (30). Oxidative DNA lesions that are not removed prior to DNA replication can lead to replication errors, mutations, and genome instability increasing the risk of carcinogenesis (31).

ROS also indirectly increase cancer risk if they cause lesions on tumor suppressor genes or inactivate negative regulators of oncogenes and DNA repair proteins (32, 33). Under physiological conditions, ROS accumulation is regulated by endogenous enzymatic and non-enzymatic antioxidant defense systems (26). Oxidative stress occurs when ROS levels outstrip these cellular antioxidant defenses (34). Oxidative stress has been linked to PCa development and progression. In Nkx3.1−/− mutant mice, dysregulation in the expression of antioxidant and prooxidant enzymes led to oxidative stress and development of HGPIN while Nkx3.1/Pten double mutants which sustained more oxidative damage progressed to adenocarcinoma (35).

Products of oxidative damage; 8-hydroxy-2′-deoxyguanosine, 4-hydroxynonenal-protein-adducts, and nitrotyrosine were also detected in early prostatic tumorigenesis in the transgenic adenocarcinoma of the mouse prostate model (36). In the noble rat hormonal PCa model, administration of testosterone and β-estradiol triggered the expression of prooxidant enzymes and oxidative damage which induced stromal inflammation and dysplasia in the lateral prostate (37). For humans, several PCa risk factors including age, diet, inflammation and androgens are also associated with oxidative stress (38).

Additionally, key genetic and epigenetic changes in PCa have been shown to decrease the expression of genes relevant to prostatic redox homeostasis like GSTP1, Nrf2, NKX3.1, and NADPH oxidases (35, 39–41). Besides, transcription factors important for PCa like NK-Xb, AP-1, HIF-1, and p53 are redox sensitive (42). Relative to benign prostate cells, human PCa cell lines display higher oxidative stress which is associated with a more aggressive phenotype (39). Moreover, as PCa progresses, patients display increasing levels of oxidative biomarkers including thiobarbituric acid reactive substances, 8-hydroxy-2′-deoxyguanosine and 4-hydroxynonenal-modified proteins concomitant with loss of antioxidant defenses (43–48).

**THE SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)**

The links between oxidative stress and PCa pathogenesis are the basis of the notion that use of antioxidants can reduce risk of the disease. The SELECT trial tested the efficacy of the antioxidants selenium and vitamin E in reducing PCa incidence in 35,533 men over the age of 50 with an intended follow up of 12 years (49, 50). As part of the inclusion criteria, the men had to be free of a prior PCa diagnosis, have a non-suspicious digital rectal examination and a serum prostate specific antigen level of ≤ 4 ng/mL (50). SELECT, a phase III clinical trial, randomized participants to a daily dose of 200 μg L-selenomethionine and/or 400 IU α-tocopheryl acetate or placebo (49, 50). After 7 years of follow up, it was found that neither antioxidant reduced PCa incidence and that vitamin E was associated with a 17% increased risk of PCa compared to placebo (51).

**IN VITRO MODELS OF ADVANCED DISEASE DID NOT PREDICT OUTCOME OF A PRIMARY CHEMOPREVENTION CLINICAL TRIAL**

Numerous *in vitro* studies suggest that vitamin E and selenium are antitumorigenic by inhibiting proliferation, altering redox homeostasis, inducing apoptosis, suppressing androgen receptor signaling, blocking inflammatory signaling among other mechanisms (52–92). SELECT’s lack of efficacy and harmful effects however indicate that traditional *in vitro* models had a low predictive value for the clinical trial outcome (93, 94). In addition, the majority of *in vitro* chemoprevention studies predominantly use cell lines derived from advanced cancers including LNCaP, DU145, and PC3. These do not model disease initiation and they did not predict the outcome of a primary chemoprevention clinical trial like SELECT (94).

Cells at different stages of cancer progression likely respond differently to antioxidants due to differential regulation of prooxidant and antioxidant networks (95). ROS accumulation due to decreased antioxidant activity in premalignant lesions and early stage cancers could promote tumorigenesis through DNA damage and inactivating tumor suppressors (95).
Advanced cancers however counter high ROS accumulation by increasing antioxidant activity through several mechanisms like upregulating NRF2 or increasing metabolic generation of reducing equivalents like NADPH mitigating oxidant damage (95).

**INCREASING THE PREDICTIVE VALUE OF PRECLINICAL RESEARCH BY USING THREE DIMENSIONAL CELL CULTURES**

*In vitro* testing of chemoprevention agents has historically utilized conventional two dimensional (2D) culture which does not recapitulate *in vivo* prostate biology. The human prostate is a multicellular secretory epithelium with a central lumen (96). The prostate's luminal layer is made of polarized columnar luminal epithelial cells which face the lumen and produce prostatic secretions (96). The prostate epithelium sits upon a basement membrane which is surrounded by a stromal compartment (97). Basement membranes are cell adherent sheet-like structured extracellular matrices (ECMs) that include laminins, collagens, proteoglycans, and glycoproteins (98). The ECM provides physical support and serves as a scaffold for tissue organization (99).

In addition, ECM attachment provides biochemical and mechanical cues necessary for anchorage dependent cell growth, proliferation, migration, and differentiation (99). ECM proteins bind growth factors, cytokines and chemokines creating spatial and temporal concentration gradients necessary for spatiotemporal coordination of cellular activity during tissue morphogenesis, wound healing, and chemotaxis (100). Integrins which link the ECM and the actin cytoskeleton also transmit external mechanical and internal actomyosin contractile forces from and to the ECM altering cell migration, proliferation, and differentiation (101).

During normal epithelial glandular development, ECM–cell interactions provide contextual cues needed to maintain apico-basal polarity necessary for correct tissue architecture and function (102). The ECM aligns the mitotic spindle perpendicular to the apical–basal axis enabling symmetrical cell division in the plane of the monolayer which maintains tissue structure (102). ECM–cell interactions balance proliferation and cell death for tissue homeostasis and lumen morphogenesis; their disruption contribute to neoplastic transformation (99, 103). In contrast, cells in 2D culture lack physiological cell–cell and cell–matrix interactions leading to loss of native tissue architecture and function (104).

Additionally, attachment of the 2D monolayer to artificial surfaces affects cell morphology and signaling (105, 106). This has been attributed to the high failure rate of drugs screened using 2D *in vitro* cultures in clinical trials (107). Moreover, 2D cultures have a non-physiologically uniform distribution of oxygen and nutrients (108). Embedding cells in three dimensional (3D) matrices yields more physiological cell-cell and cell-matrix interactions. Organoids are 3D cellular aggregates derived from primary tissues/cells, induced pluripotent stem cells, or embryonic stem cells, which self-renew and self-organize to exhibit similar architecture and functionality as their tissue of origin (109). Organoids can also be derived from established cell lines (110).

Organoid self-renewing property lends itself well to a host of basic and translational research applications. It allows the expansion of cells from minuscule patient samples like solid tumor biopsies and circulating tumor cells for liquid biopsies, facilitating genetic profiling, drug screening, and potentially guiding personalized therapy (111, 112). Organoids can also be harnessed to study tissue development including embryonic development, lineage specification, tissue morphogenesis, and homeostasis and how these processes change during disease (113, 114). For example, organoids have been utilized to investigate the PCA cell of origin which could have prognostic and treatment benefits (115–118). Organoid co-cultures with stromal components will allow research in to the contribution of the tumor microenvironment to malignancy (119).

Prostate organoids phenocopy *in vivo* glandular morphology; they undergo polarization, lumen formation and produce prostatic secretions (115). Unlike 2D cultures, growth factor, nutrients and oxygen gradients in organoids yield heterogeneous cell populations like *in vivo* (107). Additionally avascular organoids better model solid tumors which are often poorly vascularized *in vivo*. Similar to tumors, cells at the center of large organoids are under various stresses including loss of ECM attachment and limits in the diffusion of nutrients and oxygen (120). This *in vivo*-like physiology of organoid cultures could increase the predictive value of preclinical research (107). Moreover, organoid cultures bridge the gap between 2D and animal models, that are challenging to generate for example the genetically engineered mouse models and which are affected by interspecies differences (121).

**PREMALIGNANT ORGANOIDS RECAPITULATE OUTCOME OF THE SELECT TRIAL**

Effects of the mean concentrations of the SELECT agents attained in the blood plasma of the SELECT participants was evaluated in prostate organoids derived from normal, premalignant, and malignant prostate epithelial cells (122). The benign organoids were obtained from histologically and genetically normal prostate epithelium isolated from radical prostatectomy tissue (122). The premalignant organoids were derived from the untransformed RWPE-1 cell line which is immortalized with the E7 oncoprotein, modulating the activity of the retinoblastoma tumor suppressor (123, 124). The malignant organoids were cultured from the androgen responsive LNCaP cell line established from a lymph node PCA metastasis (125).

The vehicle-treated malignant organoids were devoid of lumens (filled morphology) a phenotype consistent with the acquisition of anchorage independent survival and loss of glandular differentiation (122). In contrast, normal epithelial cells require ECM attachment for proliferation and survival (99). This is partly because integrin ligation to the ECM regulates growth factor signaling and cell cycle progression (99). In these
cells, ECM detachment activates a form of apoptotic cell death termed “anoikis,” which is Greek for homelessness (126). Anoikis clears cells in inappropriate locations preventing dysplastic growth (126). Anoikis also contributes to tissue homeostasis by eliminating cells without ECM contact in the lumen, hollowing glands (127).

Focal loss of ECM and integrin attachment in prostatic intraepithelial neoplasia lesions leads to cells proliferation within the lumen leading to defective glandular structures (128). In addition, PCa progression is marked by a gradual loss of glandular lumina (129). In cancer cells, oncogene activation overrides the requirement for ECM-adhesion leading to anchorage independent growth and resistance to anoikis (126). The SELECT agents decreased proliferation and increased cell death in the ECM distal cells at the center of the malignant organoids (122). This is consistent with reports that show antioxidant efficacy in PCa cell lines (60, 61). In contrast, the agents had no effect on the proliferation of benign organoids (122). Morphologically, the benign organoids had proper glandular structure with well-formed lumens which was not affected by vitamin E and/or selenium treatment (122).

The null effect of antioxidants on the benign organoids is consistent with SELECT where a fraction more subjects on vitamin E developed PCa compared to placebo (51). We posit that these individuals might have harbored initiated cells that progressed to neoplastic transformation with chronic vitamin E exposure. In agreement with this hypothesis, vitamin E alone or in combination with selenium but not selenium alone significantly increased the proliferation of premalignant RWPE-1 cell organoids (122). Therefore only results from the premalignant organoids recapitulated the clinical trial data from SELECT.

Our group has previously demonstrated that the antioxidant NAC causes premalignant prostatic epithelial hyperplasia in mice with prostate specific deletion of the Nkx3.1 tumor suppressor but not in wild type mice (130). In addition, polymorphisms in Nkx3.1 were found to modulate PCa risk in men on the interventional arms of the SELECT trial (131). This points to the importance of the underlying genetic background in modifying the response to antioxidant supplementation. However, SELECT’s inclusion criteria; prostate-specific antigen levels and a non-suspicious digital rectal exam, could not rule out the existence of initiating molecular aberrations (132).

Additionally, while the vehicle treated premalignant RWPE-1 organoids had more differentiated acinus structures and predominantly hollow lumens those treated with vitamin

---

**FIGURE 1** Model of anchorage-dependent regulation of cell survival and glucose metabolism. Adhesion of cells to the ECM activates integrins and receptor tyrosine kinase (RTK) signaling which triggers different pro-survival and proliferation pathways like AKT and MAPK. AKT inhibits BIM, a pro-apoptotic protein preventing anoikis and increases glucose uptake and glycolysis by upregulating the transcription of glucose transporters (GLUT1) and hexokinase 2 (HK2) respectively. Oxidative phosphorylation (OXPHOS) of pyruvate derived from glucose yields ATP for cellular function. Glucose shunted through the PPP pathway generates NADPH which prevents ROS induced cell death.
E had predominantly filled lumens (122). Microarray analysis of RNA extracted from vitamin E treated RWPE-1 organoids displayed significant downregulation of several integrins confirming the loss of matrix attachment (122). Vitamin E therefore increases cell survival in a low matrix environment (122).

**ECM DETACHED RWPE-1 CELLS HAVE DEFICIENT GLUCOSE METABOLISM WHICH VITAMIN E ALLEVIATES BY ACTIVATING FATTY ACID OXIDATION**

Despite increased cell growth and survival, the vitamin E treated premalignant organoids had decreased expression of glucose transporters and several glycolytic enzymes implying glucose metabolism dysregulation (122). To further study metabolic changes in RWPE-1 cells under anchorage independent conditions *in vitro*, Poly-2-hydroxyethyl methacrylate (Poly-HEMA), suspension cultures were used (122). Poly-HEMA, a non-ionic polymer prevents ECM deposition on tissue culture plates and cell adhesion (126, 133). Additionally, growth of human epithelial cancer cells on poly-HEMA coated plates correlates with *in vitro* growth in soft agar the gold standard for measuring anchorage independent growth and tumorigenicity (134, 135).

Poly-HEMA cultures therefore provide a model for studying the regulation of anchorage-independent cell survival and growth for studies that are difficult to perform in organoids (136). Glucose is catabolized to Acetyl-CoA whose oxidative phosphorylation in the mitochondria produces reducing equivalents which mediate electron transfer in the electron transport chain generating the proton motive force that drives ATP synthesis (137). RWPE-1 poly-HEMA cultures had reduced glucose uptake and ATP levels confirming that loss of attachment jeopardizes cellular metabolism (122). Similar observations have been reported in detached MCF-10A benign breast epithelial cells (138).

Altered metabolism after cell detachment has been attributed to the loss of integrin activation of the PI3K/AKT pathway which is a crucial regulator of glucose and glutamine uptake and metabolism (138). ECM-integrin contact leads to the recruitment of adopter proteins like talin and paxillin as well as signaling molecules like focal adhesion kinase (Fak) and small GTPases to form large macromolecular structures termed focal adhesions connecting the ECM and the actin cytoskeleton (139). Autophosphorylation of FAK (Y397) downstream of integrin signaling activates its kinase function leading to the activation of the SRC/MAPK and PI3K/AKT pathways which are crucial for progression through the G1/S checkpoint, cell survival and proliferation (Figure 1) (140, 141).

Cross talk between integrins and receptor protein tyrosine kinases also activates the PI3K/AKT pathway downstream of the epidermal growth factor receptor (142). In contrast, the accumulation of multiple alterations allows cancer cells to circumvent such extracellular regulation enabling them to uptake nutrients constitutively (137). Glucose can also be shunted through the pentose phosphate pathway to

**FIGURE 2 |** Model of vitamin E-mediated cell survival in ECM detached cells. Due to loss of integrin and PI3K signaling, cell detachment from the ECM results in the reduced expression of glucose transporters and low glucose uptake (shown in broken lines and gray boxes). This decreases ATP production and cell survival. Moreover, low NADPH generation through attenuated PPP flux leads to ROS accumulation which can induce cell death. ROS also inhibits fatty acid beta-oxidation (FAO) an alternative ATP generation pathway under glucose limiting conditions. However, treating detached cells with exogenous antioxidants like vitamin E neutralizes ROS which activates FAO increasing cell survival. Attenuating FAO using etomoxir which inhibits carnitine palmitoyltransferase (CPT1), FAO’s rate limiting enzyme, abrogates vitamin E’s ATP rescue ultimately diminishing cell survival.
generate the reducing equivalent NADPH and the nucleotide structural component, ribose-5-phosphate (137). In detached mammary cells low glucose uptake not only reduces ATP generation but also diminishes pentose phosphate pathway flux and NADPH production leading to ROS accumulation (Figure 2) (138).

Treatment of detached RWPE-1 cells with vitamin E rescued ATP generation but not glucose uptake (122). Similar findings have been reported in detached mammary cells treated with NAC or trolox, a soluble form of vitamin E (138). When glucose is scarce, cells can catabolize fatty acids for ATP generation. In Akt transformed glioblastoma, cells activate fatty acid oxidation to survive upon glucose withdrawal (143). It has been postulated that ROS inhibits fatty acid oxidation and hydrogen peroxide a form of ROS, has been shown to inhibit peroxisomal FAO (144–146). Pharmacological inhibition of fatty acid oxidation in vitamin E detached RWPE-1 cells abrogated the ATP rescue indicating that the antioxidant activates fatty acid catabolism (122).

Furthermore, fatty acid oxidation inhibition decreased cell survival and enhanced luminal clearance in vitamin E treated premalignant organoids indicating that antioxidants support anchorage independent cell survival (122). Moreover, other antioxidant-driven metabolic rescue mechanisms following loss of matrix attachment have also been described (147). In lung cancer spheroids, loss of matrix attachment upregulates glutamine reductive metabolism by cytosolic isocitrate dehydrogenase-1 to generate NADPH which is shuttled to inhibit mitochondrial ROS, enhancing cell growth (147). However, despite lowering ROS levels, selenium was not protumorigenic on the premalignant organoids (122). The effect of selenium on PCa risk has been shown to depend on baseline selenium status (148).

CONCLUSIONS

The data showing antitumorigenic effects of antioxidants on malignant organoids replicates numerous two dimensional in vitro studies. However, 3D organoids starkly reveal differential effects of antioxidants along the prostate cancer evolution spectrum. In this system, vitamin E had a null effect in benign organoids and a pro-tumorigenic effect in premalignant organoids in a manner highly reminiscent of the SELECT trial results. These findings demonstrate that the use of preclinical models that better mimic in vivo conditions and disease stage yield data that is more relevant for clinical translation.

More broadly, organoid data in several cancers now show that neutralizing ROS promotes anchorage independent cell growth and survival implying that ROS accumulation can imperil detached cells (122, 138, 147). Anchorage independence facilitates cell growth and survival in non-native environments for example in metastasis (149). Therefore, identifying mechanisms that enable anchorage independence could offer clues on how to impede cancer metastasis (149). Finally, given the role that metabolism plays in carcinogenesis, preclinical studies ought to include metabolic endpoints when assessing potential chemopreventive agents.

AUTHOR CONTRIBUTIONS

SA and RN contributed to conception and design of the manuscript. RN researched supporting evidence and wrote the manuscript. RV and SA contributed to critical revision of content and figure design. SA secured grant funding.

FUNDING

This work was supported by NCI grants 1P50CA180995, R01CA123484, and R01 CA167966.
in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. (2015) 16:152–60. doi: 10.1016/S1470-2045(14)71205-7
12. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in metastatic prostate cancer after chemotherapy. N Engl J Med. (2012) 367:1187–97. doi: 10.1056/NEJMoa1207506
13. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. (2010) 363:411–22. doi: 10.1056/NEJMoa101294
14. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger MJ, Tannock IF. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. J Urol. (2007) 178(4 Pt 1):1238–43; discussion 43–4.
15. Thomson IM, Goodman PJ, Tangen CM, Paraiso M, Thompson JA, Young WP, et al. Reflections on a diagnostic and therapeutic dilemma: prostate cancer. J Med. (2004) 349:215–24. doi: 10.1056/NEJMoa030660
16. Hammarstrom KM, Finkel T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat Rev Mol Cell Biol. (2014) 15:411–21. doi: 10.1038/nrm3801
17. Kalyanaraman B. Teaching the basics of redox biology to medical and graduate students: Oxidants, antioxidants and disease mechanisms. Redox Biol. (2013) 1:244–57. doi: 10.1016/j.redox.2013.09.014
18. Cadet J, Wagner JR. DNA base damage by reactive oxygen species, oxidizing agents, and UV radiation. Cold Spring Harbor Perspect Biol. (2013) 5:a012559. doi: 10.1101/cshperspect.a012559
19. Sakr WA, Partin AW. Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia: a prospective controlled study. Urology. (2003) 62:1192–202. doi: 10.1016/S0090-4295(03)00945-3
20. Thompson IM, Goodman PJ, Tangen CM, Paraiso M, Thompson JA, Young WP, et al. Reflections on a diagnostic and therapeutic dilemma: prostate cancer. J Med. (2004) 349:215–24. doi: 10.1056/NEJMoa030660
21. Cameron DA, Partin AW. Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia: a prospective controlled study. Urology. (2003) 62:1192–202. doi: 10.1016/S0090-4295(03)00945-3
22. Thompson IM, Goodnow PJ, Tangen CM, Paraiso M, Thompson JA, Young WP, et al. Reflections on a diagnostic and therapeutic dilemma: prostate cancer. J Med. (2004) 349:215–24. doi: 10.1056/NEJMoa030660
23. Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C. Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res. (2005) 65:6773–9. doi: 10.1158/0008-5472.CAN-05-1948
24. Tam NN, Nyska A, Maronpot RR, Kissling G, Lomnitzi L, Suttie J, et al. Differential attenuation of oxidative/nitrosative injuries in early prostate neoplastic lesions in TRAMP mice by dietary antioxidants. Prostate (2006) 66:57–69. doi: 10.1002/pro.20313
25. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. J Med. (2004) 349:215–24. doi: 10.1056/NEJMoa030660
26. Yossepowitch O, Pinchuk I, Gur U, Neumann A, Lichtenberg D, Baniel J. Advanced but not localized prostate cancer is associated with increased oxidative stress. J Urol. (2007) 178(4 Pt 1):1238–43; discussion 43–4. doi: 10.1016/j.juro.2007.05.145
27. Aydin D, Arsova-Sarafinovska Z, Sayal A, Eken O, Erdem O, Erten K, et al. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin Biochem. (2006) 39:176–9. doi: 10.1016/j.clinbiochem.2005.11.018
28. Arsova-Sarafinovska Z, Eken A, Matevska N, Erdem O, Sayal A, Savašer A, et al. Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem. (2009) 42:1228–35. doi: 10.1016/j.clinbiochem.2009.05.009
29. Kaya E, Özgök Y, Zor M, Eken A, Bedir S, Erdem O, et al. Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: a prospective controlled study. Adv Clin Exp Med. (2017) 26:1095–9. doi: 10.21793/acem/66837
30. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2009) 301:39–51. doi: 10.1001/jama.2008.864
64. Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S. Vitamin E succinate induces apoptosis in prostate cancer cells. *Cancer Res.* (2000) 60:50–54. doi: 10.1158/0008-5472.CAN-99-0053

66. Jia L, Yu W, Wang P, Li J, Sanders BG, Kline K. Critical roles for JNK, c-Jun, c-Jun N-terminal kinase 1, and other antioxidants inhibit human prostate cancer cell lines. *Mol Cancer* (2011) 10:134–43. doi: 10.1186/1476-4598-10-13

68. Zhong W, Oberley TD. Redox-mediated effects of selenium on apoptosis and cell survival. *Cancer Lett.* (2006) 249:1–16. doi: 10.1016/j.canlet.2006.04.004

69. Webber MM, Perez-Ripoll E, James GT. Inhibitory effects of vitamin E derivative, RRR-alpha-tocopherylxybutyric acid inhibits the proliferation of prostate cancer cells. *Cancer Chemother Pharmacol.* (2005) 55:550–8. doi: 10.1007/s00280-005-0234-3

70. He Q, Rashid A, Rong R, Hillman MJ, Huang Y, Sheikh MS. Death receptor 5 regulation during chemotherapeutic apoptosis in human prostate cancer cells. *Cancer Biol. Ther.* (2002) 1:287–90. doi: 10.4161/cbt.83

72. Gasparian AV, Yao YJ, Lu JX, Yemelyanyov AY, Lyakh LA, Slaga TJ, et al. Selenium compounds inhibit I kappa B kinase (IKK) and nuclear factor-kappa B (NF-kappa B) in prostate cancer cells. *Mol Cancer Ther.* (2002) 1:1079–87.

73. Christensen MJ, Nartey ET, Hada AL, Legg RL, Barzee BR. High selenium reduces NF-kappaB-regulated gene expression in uninduced human prostate cancer cells. *Mol Cancer* (2007) 5:197–204. doi: 10.1016/j.molcancer.2007.07.001

74. Lu Z, Qi L, Li GX, Bo XJ, Liu GD, Wang JM. Selenium reduces NF-κB activation and enhances apoptosis Mediated by vitamin E analog in human prostate cancer cells. *Mol Cancer* (2010) 9:1–10. doi: 10.1186/1476-4598-9-1.

75. Whanger PD. Selenium and its relationship to cancer: an update. *J Nutr.* (2004) 134:11–28. doi: 10.1093/jn/20030105

76. Constantino C, Papas A, Constantino AI. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. *Int J Cancer* (2008) 123:739–52. doi: 10.1002/ijc.23689

77. Gunawardena K, Murray DK, Meikle AW. Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis. *Prostate* (2000) 44:287–95. doi: 10.1002/1097-0045(20000901)44:4<287::AID-JPROS10>3.0.CO;2-Z

78. Liu SA, Zhang HT, Zhu LY, Zhao LJ, Dong Y. Kruppel-like factor 4 is a novel mediator of selenium in growth inhibition. *Mol Cancer Res.* (2005) 3:1079–87. doi: 10.1158/1535-7163.MCR-05-0013

79. Cho SD, Jiang C, Malewicz B, Dong Y, Young CY, Kang KS, et al. Methyl selenium metabolites decrease prostate-specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. *Cancer Res.* (2004) 64:19–22. doi: 10.1158/0008-5472.CAN-03-2789

80. Cho SD, Jiang C, Malewicz B, Dong Y, Young CY, Kang KS, et al. Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. *Mol Cancer Ther.* (2005) 4:3605–11. doi: 10.1158/1535-7163.MCT-04-0612

81. Zhu N, Yi L, Messing EM, Chang E, Yang CR, Yeh S. Vitamin E succinate inhibits the androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. *Prostate* (2000) 40:107–13. doi: 10.1002/1097-0045(20000801)40:1<107::AID-JPROS4>3.0.CO;2-S

82. Redman C, Scott JA, Baines AT, Basye JL, Clark LC, Calley C, et al. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. *Cancer Lett.* (1998) 125:103–10. doi: 10.1016/S0304-3835(97)00497-7

83. Zhong W, Oberley TD. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. *Cancer Res.* (2001) 61:7071–8.

84. Jobe DJ, Hruban RH, Budhu A, Grandis JR, Prado I, Longley DA, et al. Enhanced selenium effect on growth arrest by BIP/GRP78 knockdown in p53-null human prostate cancer cells. *Oncogene* (2006) 25:546–54. doi: 10.1038/sj.onc.1209071

85. Njoroge et al. Organoids Are Predictive of Clinical Outcome
human prostate cancer cells. *Cancer Chemother Pharmacol.* (2009) 63:351–62. doi: 10.1007/s00028-008-0745-3

89. Li GX, Hu H, Jiang C, Schuster T, Lu J. Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells. *Int J Cancer* (2007) 120:2034–43. doi: 10.1002/ijc.22480

90. Berggren M, Sittadjody S, Song Z, Samira JL, Burd R, Meuillet EJ. Sodium selenite increases the activity of the tumor suppressor protein, PTEN, in DU-145 prostate cancer cells. *Natr Cancer* (2009) 61:322–31. doi: 10.1080/16355880802521338

91. Xiang N, Zhao R, Song G, Zhong W. Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells. *Carcinogenesis* (2008) 29:2175–81. doi: 10.1093/carcin/bgn179

92. Hurst R, Elliott RM, Goldson AJ, Fairweather-Tait SJ. Se-methylselenocysteine alters collagen gene and protein expression in human prostate cells. *Cancer Lett.* (2008) 269:117–26. doi: 10.1016/j.canlet.2008.04.025

93. Bosland MC, Ozen N, Eskra JN, Mahmoud AM. A perspective on prostate carcinogenesis and chemoprevention. *Curr Pharmacol Rep.* (2013) 1:258–65. doi: 10.1007/s40495-015-0031-0

94. Bosland MC. Is There a Future for Chemoprevention of Prostate Cancer? *Cancer Prev Res.* (2016) 9:642–7. doi: 10.1158/1940-6207.CAPR-16-0088

95. Assi M. The differential role of reactive oxygen species in early and late stages of cancer. *Am J Physiol Regul Integr Comput Physiol.* (2017) 313;R464–53. doi: 10.1152/ajpregu.00247.2017

96. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. *Carcinogenesis* (2008) 29:2175–81. doi: 10.1093/carcin/bgn179

97. Kruger JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. *Cell* (2014) 159:163–75. doi: 10.1016/j.cell.2014.08.017

98. Park JW, Lee JK, Phillips JW, Huang P, Cheng D, Huang J, et al. Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. *Proc Natl Acad Sci USA.* (2016) 113;4482–7. doi: 10.1073/pnas.1603645113

99. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. *Dev Rep.* (2013) 15:1243–53. doi: 10.1016/j.cellrep.2013.04.026

100. Wang S, Gao D, Chen Y. The potential of organoids in urologic al cancer research. *Nat Rev Urol.* (2017) 14:601–14. doi: 10.1038/nrurol.2017.65

101. Wang N, Suo Z. Long-distance propagation of forces in cell. *Biochem Biophys Res Commun.* (2005) 328:1133–8. doi: 10.1016/j.bbrc.2005.01.070

102. Roignot J, Peng X, Mostov K. Polarity in mammalian epithelial morphogenesis. *Cold Spring Harbor Perspect Biol.* (2013) 5:a013789. doi: 10.1101/cshperspect.a013789

103. Xia J, Swiercz JM, Banon-Rodriguez I, Matkovic I, Federico G, Sun T, et al. Semaphorin-plexin signaling controls mitotic spindle orientation during epithelial morphogenesis and repair. *Dev Cell* (2015) 33:299–313. doi: 10.1016/j.devcel.2015.02.001

104. Xie R, Boudreau A, Bissell MJ. Tissue architecture and functi on: dynamic 3D and animal models: are 3D cultures the ideal tool to study cancer-microenvironment interactions? *Int J Mol Sci.* (2018) 19:E181. doi: 10.3390/ijms19010181

105. Simian M, Bissell MJ. Organoids: a historical perspective of thinking in three dimensions. *J Cell Biol.* (2017) 216:31–40. doi: 10.1083/jcb.201610056

106. Edmondson R, Broglio JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. *Assay Drug Dev Technol.* (2014) 12:207–18. doi: 10.1089/adt.2014.573

107. Antoni D, Burckel H, Josset E, Noel G. Three-dimensional cell culture: a breakthrough in vivo. *Int J Mol Sci.* (2015) 16:5317–27. doi: 10.3390/ijms16035517

108. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. *Science.* (2015) 345:1247125. doi: 10.1126/science.1247125
132. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, et al. SELECT: the selenium and vitamin E cancer prevention trial. *Urol Oncol Semin Ori* (2003) 21:59–65. doi: 10.1016/S1078-1439(02)00301-0

133. Folkman J, Moscona A. Role of cell shape in growth control. *Nature* (1978) 273:345–9. doi: 10.1038/273345a0

134. Rotem A, Janzer A, Izar B, Ji Z, Doench JG, Garraway LA, et al. Alternative to the soft-agar assay that permits high-throughput genetic screens for cellular transformation. *Proc Natl Acad Sci USA*. (2015) 112:5708–13. doi: 10.1073/pnas.1505979112

135. Fukazawa H, Nakano S, Mizuno S, Uehara Y. Inhibitors of anchorage-independent growth affect the growth of transformed cells on poly(2-hydroxyethyl methacrylate)-coated surfaces. *Int J Cancer* (1996) 67:876–82. doi: 10.1002/(SICI)1097-0215(19960917)67:6<876::AID-IJC19>3.0.CO;2-#

136. Grassian AR, Coloff JL, Brugge JS. Extracellular matrix regulation of metabolism and implications for tumorigenesis. *Cold Spring Harbor Symp Quant Biol*. (2011) 76:313–24. doi: 10.1101/sqb.2011.76.010967

137. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. *Cell Metab*. (2016) 23:27–47. doi: 10.1016/j.cmet.2015.12.006

138. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. *Nature* (2009) 461:109–13. doi: 10.1038/nature08268

139. Geiger B, Bershadsky A, Pankov R, Yamada KM. Transmembrane crosstalk between the extracellular matrix–cytoskeleton crosstalk. *Nat Rev Mol Cell Biol*. (2001) 2:793–805. doi: 10.1038/35099066

140. Xia H, Nho RS, Kahm J, Kleidon J, Henke CA. Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta(1) integrin viability signaling pathway. *J Biol. Chem.* (2004) 279:33024–34. doi: 10.1074/jbc.M313265200

141. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. *Nat Rev Mol Cell Biol*. (2005) 6:56–68. doi: 10.1038/nrm1549

142. Cabodi S, Moro L, Bergatto E, Boeri Erba E, Di Stefano P, Turco E, et al. Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. *Biochem Soc Trans*. (2004) 32(Pt3):438–42. doi: 10.1042/bst0320438

143. Buzzai M, Bauer DE, Jones RG, DeBerardinis RJ, Hatzivassiliou G, Elstrom RL, et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta oxidation. *Oncogene* (2005) 24:4165–73. doi: 10.1038/sj.onc.1208622

144. Sheikh FG, Pahan K, Khan M, Barbosa E, Singh I. Abnormality in catalase import into peroxisomes leads to severe neurological disorder. *Proc Natl Acad Sci USA*. (1998) 95:2961–6. doi: 10.1073/pnas.95.6.2961

145. Gulati S, Amin L, Orak J, Singh AK, Singh I. Alterations of peroxisomal function in ischemia-reperfusion injury of rat kidney. *Biochim Biophys Acta* (1993) 1182:291–8. doi: 10.1016/0925-4439(93)90071-8

146. Hashimoto F, Hayashi H. Significance of catalase in peroxisomal fatty acyl-CoA beta-oxidation: NADH oxidation by acetocet-CoA and H2O2. *J Biochem*. (1990) 108:426–31. doi: 10.1093/oxfordjournals.jbchem.a123217

147. Jiang L, Shestov AA, Swain P, Yang C, Parker SJ, Wang QA, et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. *Nature* (2016) 532:255–8. doi: 10.1038/nature17393

148. Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RR, Thompson PA, et al. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. *Prostate* (2013) 73:328–35. doi: 10.1002/pros.22573

149. Ishikawa F, Ushida K, Mori K, Shibamura M. Loss of anchorage primarily induces non-apoptotic cell death in a human mammary epithelial cell line under atypical focal adhesion kinase signaling. *Cell Death Dis*. (2015) 6:e1619. doi: 10.1038/cddis.2014.583

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Njoroge, Vatapalli and Abdulkadir. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.